MARK BERTHOLD-LOSLEBEN
CURRENT POSITIONS
Since 05/2023
Senior Consultant Psychiatrist
Ketamine Unit and Innovative Treatment Research, Østfold Hospital Trust, Moss, Norway
Since 10/2018
Associate Professor
Department of Mental Health, NTNU Norwegian University of Science and Technology, Trondheim, Norway
FORMER POSITIONS
09/2022 – 05/2023
Senior Consultant Psychiatrist, Acute Outpatient Care, Østfold Hospital Trust, Moss, Norway
09/2014 – 08/2022
Senior Consultant Psychiatrist, St. Olavs Hospital, Trondheim University Hospital, Norway
Acute Outpatient Care, Older Age Psychiatry, Inpatient Care
04/2020 – 05/2020
Guest Researcher, Carver College of Medicine, Department of Psychiatry, University of Iowa, USA
10/2018 – 09/2022
Leader of the Teaching Unit for Adult Psychiatry, Department of Mental Health
NTNU Norwegian University of Science and Technology, Trondheim, Norway
02/2008 – 04/2013 and 05/2014 – 07/2014
Resident in Psychiatry, RWTH University Hospital Aachen
Department of Psychiatry, Psychotherapy and Psychosomatics, Germany
05/2013 – 04/2014
Resident in Neurology, Medical Centre Aachen, Department of Neurology, Germany
04/2011 – 03/2013
Postdoc, RWTH University Hospital Aachen and Jülich Research Centre, Germany
01/2007 – 01/2008
Resident in Cardiology, Department of Cardiology, Robert-Koch-Hospital Gehrden, Germany
CURRENT RESEARCH PROJECTS
PreKET: Precision medicine approach to ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (EU CT number 2025-521330-29-00). Role: National co-coordinating investigator and local PI. Funded with NOK 24.9 million by KlinBeForsk.
MM-paTh-Y: An open-label, phase 2, proof of principle study of manualized MDMA-assisted therapy for young adults with treatment-resistant depression or persistent depressive disorder. Role: Co-PI (and co-supervisor in the associated PhD project). Funded with SEK 5 million by Norssken Mind. Applied for additional NOK 4 million from South-Eastern Norway Regional Health Authority (HSØ).
KetObs: Ketamine for treatment-resistant depression – A real-world observational study of predictors of treatment response and outcome. Role: PhD main supervisor. Funded with NOK 4 million by HSØ.
MAT-MDD: An Open-Label, Phase 2, Proof-of-Principle Study of Manualized MDMA-Assisted Therapy in Subjects with MDD. Role: Project team member. Funded with NOK 4 million by HSØ.
PLANNED RESEARCH PROJECTS
PreDIKT: The Role of Subjective Experience in Predicting Treatment Response to Intravenous Ketamine in Treatment-Resistant Depression. Role: PhD main supervisor (and co-CI and local PI in the main project PreKET). Applied for NOK 4 million from HSØ.